Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, United Therapeutics Corp’s stock clocked out at $432.66, up 1.70% from its previous closing price of $425.42. In other words, the price has increased by $1.70 from its previous closing price. On the day, 0.71 million shares were traded. UTHR stock price reached its highest trading level at $433.57 during the session, while it also had its lowest trading level at $422.99.
Ratios:
To gain a deeper understanding of UTHR’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.32. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 7.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on September 26, 2025, initiated with a Outperform rating and assigned the stock a target price of $569.
On June 02, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $405.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 26 ’25 when ROTHBLATT MARTINE A bought 4,000 shares for $428.20 per share.
CAUSEY CHRISTOPHER sold 1,000 shares of UTHR for $440,000 on Sep 24 ’25. The Director now owns 4,865 shares after completing the transaction at $440.00 per share. On Sep 24 ’25, another insider, ROTHBLATT MARTINE A, who serves as the Chairperson & CEO of the company, sold 4,000 shares for $434.12 each. As a result, the insider received 1,736,489 and left with 130 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, UTHR now has a Market Capitalization of 19567595520 and an Enterprise Value of 16518894592. As of this moment, United’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.89, and their Forward P/E ratio for the next fiscal year is 14.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.72. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.36 while its Price-to-Book (P/B) ratio in mrq is 2.73. Its current Enterprise Value per Revenue stands at 5.367 whereas that against EBITDA is 10.343.
Stock Price History:
The Beta on a monthly basis for UTHR is 0.63, which has changed by 0.20736706 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, UTHR has reached a high of $442.01, while it has fallen to a 52-week low of $266.98. The 50-Day Moving Average of the stock is 26.27%, while the 200-Day Moving Average is calculated to be 31.96%.
Shares Statistics:
It appears that UTHR traded 723.13K shares on average per day over the past three months and 928290 shares per day over the past ten days. A total of 45.22M shares are outstanding, with a floating share count of 43.77M. Insiders hold about 3.22% of the company’s shares, while institutions hold 97.14% stake in the company. Shares short for UTHR as of 1757894400 were 2783971 with a Short Ratio of 3.85, compared to 1755216000 on 2855183. Therefore, it implies a Short% of Shares Outstanding of 2783971 and a Short% of Float of 8.08.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 12.0 analysts currently analyzing and rating the stock of United Therapeutics Corp (UTHR).The consensus estimate for the next quarter is $6.47, with high estimates of $7.57 and low estimates of $4.24.
Analysts are recommending an EPS of between $28.05 and $24.37 for the fiscal current year, implying an average EPS of $26.59. EPS for the following year is $27.92, with 13.0 analysts recommending between $31.74 and $23.03.
Revenue Estimates
In . The current quarter, 12 analysts expect revenue to total $813.96M. It ranges from a high estimate of $868.5M to a low estimate of $778.4M. As of . The current estimate, United Therapeutics Corp’s year-ago sales were $748.9MFor the next quarter, 12 analysts are estimating revenue of $804.22M. There is a high estimate of $821.3M for the next quarter, whereas the lowest estimate is $776.83M.
A total of 14 analysts have provided revenue estimates for UTHR’s current fiscal year. The highest revenue estimate was $3.3B, while the lowest revenue estimate was $3.13B, resulting in an average revenue estimate of $3.21B. In the same quarter a year ago, actual revenue was $2.88BBased on 14 analysts’ estimates, the company’s revenue will be $3.39B in the next fiscal year. The high estimate is $3.53B and the low estimate is $3.07B.
